A seasoned pharmaceutical industry executive with over 40 years at the forefront of innovation, including at Synthelabo (acquired by Sanofi-Aventis), Dr. Angel aims to propel MIRA Pharmaceuticals' mission to tackle unmet needs in neurologic and neuropsychiatric disorders

Angel博士是一位经验丰富的制药行业高管，拥有40多年的创新前沿经验，包括在Synthelabo（被赛诺菲-安万特收购），旨在推动MIRA制药公司解决神经和神经精神疾病未满足需求的使命

MIAMI, March 21, 2024 /PRNewswire/ -- MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) ('MIRA' or the 'Company'), an innovative pre-clinical-stage pharmaceutical company focused on the development of novel treatments for neurologic and neuropsychiatric disorders, proudly announces the appointment of distinguished pharmaceutical executive Dr.

迈阿密，2024年3月21日/PRNewswire/--MIRA Pharmaceuticals Inc.（纳斯达克：MIRA）（“MIRA”或“公司”）是一家创新的临床前阶段制药公司，专注于开发神经和神经精神疾病的新型治疗方法，骄傲地宣布任命杰出的制药高管Dr。

Itzchak Angel as its new Chief Scientific Advisor..

伊扎克·安吉尔（ItzchakAngel）担任其新任首席科学顾问。。

Dr. Angel brings over 40 years of preclinical, clinical and regulatory acumen to MIRA. He has significantly contributed to the research, development and regulatory approval of groundbreaking medications over his remarkable career. Notably, at Synthelabo (later acquired by Sanofi-Aventis), Dr. Angel played a pivotal role in advancing several drugs, including Litoxetine for depression and Deriglidole for Type-II diabetes, from conception to Investigational New Drug (IND) applications and clinical trials.

Angel博士为MIRA带来了40多年的临床前，临床和监管敏锐度。在他卓越的职业生涯中，他为开创性药物的研究，开发和监管批准做出了重大贡献。值得注意的是，在Synthelabo（后来被赛诺菲-安万特收购）公司，Angel博士在从概念到研究性新药（IND）应用和临床试验的发展过程中，在推进几种药物方面发挥了关键作用，包括治疗抑郁症的利托西汀和治疗II型糖尿病的德里格利多。

Additionally, his activities contributed to the development and marketing of Mizollen (mizolastine), Xatral (alfuzosin) and Ambien (zolpidem)..

此外，他的活动还有助于Mizollen（mizolastine）、Xtral（alfuzosin）和Ambien（zolpidem）的开发和营销。。

Beyond his tenure at Synthelabo, Dr. Angel has made significant advancements in the pharmaceutical industry, including impactful work at several companies, such as Teva, where he was an external consultant in strategic drug development and innovation. He has also founded and served as an officer and director of several pharma start-ups.

在Synthelabo任职期间，Angel博士在制药行业取得了重大进展，包括在多家公司（如Teva）从事了有影响力的工作，他曾担任战略药物开发和创新的外部顾问。他还成立了多家制药初创公司，并担任其高管和董事。

He was Vice President for Research and Development at D-Pharm Biopharmaceuticals, where he advanced DP-VPA into the human trials for epilepsy and bi-polar disorders (later licensed to Shire Pharmaceuticals) and the chelator DP-b99 for stroke (which advanced to phase-III clinical trials). Dr Angel also served as President and Chief Executive Officer of stem-cell company Accellta; Vice President for Research and Development at Proteologics Ltd and at Galmed Pharmaceuticals (where he advanced Aramchol through an IND to phase-II clinical trials); Head of Discovery and Research and Development Concenter Biopharma (where he advanced Zygosid-50 towards clinical trials) and others.

他是D-Pharm Biopharmaceuticals的研发副总裁，在那里他将DP-VPA推进癫痫和两极疾病的人体试验（后来获得Shire Pharmaceuticals的许可）和中风的螯合剂DP-b99（进入III期临床试验）。Angel博士还担任干细胞公司Accellta的总裁兼首席执行官；Proteologics Ltd和Galmed Pharmaceuticals负责研发的副总裁（在那里他通过IND将Aramchol推进到II期临床试验）；Concenter Biopharma发现与研究与开发负责人（他将Zygosid-50推进临床试验）等。

His experience extends through various therapeutic areas and has led to the successful research and development of several drugs, highlighting his vast expertise and ability to bring critical treatments through the regulatory process and ultimately to market..

他的经验涵盖了各个治疗领域，并导致了几种药物的成功研究和开发，突出了他丰富的专业知识和能力，能够通过监管过程并最终推向市场。。

Dr. Angel's extensive background in drug development, from preclinical research through clinical trials and market introduction, positions him well to contribute to MIRA's scientific endeavors. His leadership is expected to accelerate MIRA's research and development pipeline, particularly in advancing its flagship compounds, including the innovative Ketamir-2 for treatment-resistant depression..

Angel博士在药物开发方面的广泛背景，从临床前研究到临床试验和市场介绍，使他能够为MIRA的科学努力做出贡献。预计他的领导将加速MIRA的研发流程，特别是在推进其旗舰化合物方面，包括用于治疗耐药性抑郁症的创新Ketamir-2。。

'We are truly honored to have Dr. Angel on our team,' stated Erez Aminov, Chairman & CEO of MIRA. 'His distinguished career across the pharmaceutical industry, from start-ups to big pharma, his exceptional scientific skills and his dedication to pharmaceutical innovation will help propel our promising pre-clinical drug candidates forward.

MIRA董事长兼首席执行官埃雷斯·阿米诺夫（ErezAminov）表示，我们真的很荣幸能有安吉尔博士加入我们的团队他在整个制药行业的杰出职业生涯，从初创企业到大型制药公司，他出色的科学技能以及对药物创新的奉献精神，将有助于推动我们有前途的临床前候选药物的发展。

His expertise will be invaluable as we move our product candidates towards INDs and through the clinical trial and regulatory approval process and also as we seek to expand our product candidate portfolio.'.

随着我们将候选产品推向IND，通过临床试验和监管审批流程，以及我们寻求扩大候选产品组合，他的专业知识将是非常宝贵的。”。

Dr. Angel stated, 'I am thrilled to contribute to MIRA's pioneering efforts in addressing the challenges in neurologic and neuropsychiatric disorders. I look forward to applying my experience and insights to help advance MIRA.'

安吉尔博士说：“我很高兴为米拉在应对神经和神经精神疾病挑战方面的开创性努力做出贡献。我期待着运用我的经验和见解来帮助推进MIRA。”

About MIRA Pharmaceuticals, Inc.

关于MIRA Pharmaceuticals，Inc。

MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The Company's novel oral pharmaceutical marijuana, MIRA-55, is currently under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.

MIRA Pharmaceuticals，Inc.（纳斯达克：MIRA）是一家临床前阶段的药物开发公司，拥有两个针对广泛神经和神经精神疾病的神经科学项目。该公司的新型口服药物大麻MIRA-55目前正在接受调查，用于治疗患有焦虑和认知能力下降的成年患者，这些患者通常与早期痴呆症有关。

MIRA-55, if approved by the FDA, could mark a significant advancement in addressing various neuropsychiatric, inflammatory, and neurologic diseases and disorders..

如果FDA批准，MIRA-55可能标志着在解决各种神经精神疾病，炎症和神经系统疾病方面取得重大进展。。

MIRA also holds the exclusive U.S., Canadian and Mexican rights for Ketamir-2, a novel, patent pending novel oral ketamine analog under investigation to potentially deliver ultra-rapid antidepressant effects, providing hope for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation and post-traumatic stress disorder.

MIRA还拥有Ketamir-2在美国，加拿大和墨西哥的独家权利，Ketamir-2是一种正在研究中的新型专利申请新型口服氯胺酮类似物，可能产生超快速的抗抑郁作用，为患有抗药性抑郁症，具有自杀意念的重性抑郁症和创伤后应激障碍的个体提供了希望。

The U.S. Drug Enforcement Administration's scientific review of Ketamir-2 concluded that it would not be considered a controlled substance or listed chemical under the Controlled Substances Act and its governing regulations..

美国缉毒署对Ketamir-2的科学审查得出结论，根据《管制物质法》及其管理法规，它不会被视为管制物质或列出的化学品。。

Additional information about the Company is available at: www.mirapharmaceuticals.com.

有关该公司的更多信息，请访问：www.mirapharmaticals.com。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性声明的警示说明

This press release and the statements of the Company's management related thereto contains 'forward-looking statements,' which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

本新闻稿和公司管理层的相关声明包含“前瞻性声明”，即根据修订后的《1933年证券法》第27A节和修订后的《1934年证券交易法》第21E节的安全港规定做出的除历史事实以外的声明。

These statements may be identified by words such as 'Aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will,' and variations of these words or similar expressions that are intended to identify forward-looking statements.

这些陈述可以用“目标”、“预期”、“相信”、“可能”、“估计”、“期望”、“预测”、“目标”、“意图”、“可能”、“计划”、“可能”、“潜在”、“寻求”、“意志”等词语来识别，以及这些词语的变体或类似表达，旨在识别前瞻性陈述。

Any statements in this press release that are not historical facts may be deemed forward-looking. These forward-looking statements include, without limitation, statements regarding Ketamir-2's potential in treating certain mental health conditions. Any forward-looking statements in this press release are based on the Company's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond the Company's control) that could cause actual results (including the anticipated benefits Dr.

本新闻稿中任何非历史事实的声明都可能被视为具有前瞻性。这些前瞻性声明包括但不限于关于Ketamir-2治疗某些心理健康状况的潜力的声明。本新闻稿中的任何前瞻性陈述仅基于截至本新闻稿发布之日的公司当前预期、估计和预测，并受到许多可能导致实际结果（包括Dr。

Angel's services to the Company) to differ materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning the Company's programs and operations are described in additional detail in its registration statement on Form S-1 and other SEC filings, which are on file with the SEC at www.sec.gov and the Company's website at https://www.mirapharmaceuticals.com/investors/sec-filings. The Company explicitly disclaims any obligation to update any forward-looking statements except to the ext.

Angel为公司提供的服务）与此类前瞻性声明中规定或暗示的服务存在重大不利差异。与公司计划和运营有关的这些风险和其他风险在其s-1表登记声明和其他SEC文件中有详细描述，这些文件已在SEC网站www.SEC.gov和公司网站http://www.SEC.gov上存档https://www.mirapharmaceuticals.com/investors/sec-filings.公司明确否认有义务更新任何前瞻性声明，但ext除外。

SOURCE MIRA Pharmaceuticals, Inc.

来源：MIRA Pharmaceuticals，Inc。